Royalty Pharma plc - Ordinary Shares - Class A Stock

$36.51

0.75% yesterday

Nasdaq, Jul 15, 10:00 pm CET

ISIN

GB00BMVP7Y09

Symbol

RPRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Royalty Pharma plc - Ordinary Shares - Class A Stock price

$36.51

-6.49 15.09% 5Y

Nasdaq, Closing price Tue, Jul 15 2025

+0.27 0.75%

ISIN

GB00BMVP7Y09

Symbol

RPRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$20.5b

Enterprise Value

$26.3b

Net debt

$5.8b

Cash

$1.8b

Shares outstanding

566.5m

Valuation (TTM | estimate)

P/E

19.4 | 8.3

P/S

9.1 | 7.0

EV/Sales

11.6 | 8.9

EV/FCF

94.1

P/B

3.1

Dividends

DPS

$0.84

Yield 1Y | 5Y

2.3% | 1.8%

Growth 1Y | 5Y

5.0% | -

Payout 1Y | 3Y

58.3% | 70.2%

Increased

5 Years

Financials (TTM | estimate)

Revenue

$2.3b | $2.9b

EBITDA

- | $2.9b

EBIT

$1.9b | $2.8b

Net Income

$1.1b | $2.5b

Free Cash Flow

$279.8m

Growth (TTM | estimate)

Revenue

1.1% | 29.4%

EBITDA

- | 128.1%

EBIT

102.3% | 114.9%

Net Income

36.8% | 188.1%

Free Cash Flow

-72.5%

Financial Health

Equity Ratio

38.1%

Return on Equity

12.4%

ROCE

11.6%

ROIC

12.2%

Debt/Equity

1.1

EPS

$1.9

FCF per Share

$0.5

Short interest

7.0%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Get Started for Free Today

Royalty Pharma plc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

10x Buy

77%

3x Hold

23%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

Buy

77%

Hold

23%

Analyst Estimates with Stock Price Targets

Financial data from Royalty Pharma plc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2,264 2,264	1% 1% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	290 290	31% 31% 13%
- Research and Development Expense	52 52	0% 0% 2%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	1,900 1,900	102% 102% 84%
Net Profit	1,093 1,093	37% 37% 48%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Royalty Pharma plc - Ordinary Shares - Class A Stock News

Neutral

Seeking Alpha

●

15 days ago

Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks pipeline assets, with pivotal data expected in 2026. We forecast 2025 EPS of $4.53 and raise our target price to $45.3, reflecting strong earnings and capital deployment.

Positive

Reuters

●

22 days ago

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.

Neutral

GlobeNewsWire

●

22 days ago

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million. These funds will support Revolution Medicines' plans for global development and commercialization of daraxonrasib and its...

More Royalty Pharma plc - Ordinary Shares - Class A News

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.

Head office	United Kingdom
CEO	Pablo Legorreta
Founded	1996
Website	www.royaltypharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now